KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) FCF Margin (2016 - 2026)

Pacira BioSciences has reported FCF Margin over the past 17 years, most recently at 13.71% for Q1 2026.

  • For Q1 2026, FCF Margin fell 222.0% year-over-year to 13.71%; the TTM value through Mar 2026 reached 20.13%, down 255.0%, while the annual FY2025 figure was 20.72%, 478.0% down from the prior year.
  • FCF Margin for Q1 2026 was 13.71% at Pacira BioSciences, down from 29.12% in the prior quarter.
  • Over five years, FCF Margin peaked at 32.29% in Q3 2023 and troughed at 7.62% in Q4 2022.
  • A 5-year average of 18.9% and a median of 18.7% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: plummeted -4097bps in 2022 and later skyrocketed 2632bps in 2023.
  • Year by year, FCF Margin stood at 7.62% in 2022, then skyrocketed by 345bps to 18.7% in 2023, then tumbled by -35bps to 12.24% in 2024, then soared by 138bps to 29.12% in 2025, then plummeted by -53bps to 13.71% in 2026.
  • Business Quant data shows FCF Margin for PCRX at 13.71% in Q1 2026, 29.12% in Q4 2025, and 31.73% in Q3 2025.